Weld v. Glaxo Wellcome Inc.

Summary

The Massachusetts Supreme Judicial Court affirmed an order certifying a class of Massachusetts CVS pharmacy customers who received mailings generated through CVS’s patient compliance program. The court held that the named plaintiff satisfied typicality despite receiving a letter sponsored by only one pharmaceutical manufacturer because the defendants were sufficiently linked through their participation in the program. It also concluded that common issues predominated and that a class action was superior for resolving alleged privacy violations and related consumer-protection claims.

Holdings

1. Mass. R. Civ. P. 23 does not require an evidentiary hearing before a judge rules on class certification. Reviewing pleadings, affidavits, briefs, and other relevant materials may be sufficient when those materials permit a reasoned decision.
2. A representative's claims are typical when they have a sufficient relationship to the injury and conduct affecting the class and are based on the same legal theory. Kelley satisfied typicality because his injury and the class members' injuries arose from CVS's single course of conduct, and the pharmaceutical defendants were linked through substantially similar contracts and participation in the same program.
3. In this State court class action, the court analyzed Kelley's ability to represent the class under Rule 23's procedural requirements rather than treating the issue as a federal constitutional standing question.
4. Common questions predominated because liability could be determined largely through common questions concerning CVS's duty to its customers and the defendants' conduct in implementing the single program, even if damages later required individualized inquiries.
5. The class action was superior because it efficiently aggregated numerous small claims and promoted access to court and consistency of result. The possibility that certification might pressure defendants to settle, standing alone, was not a sufficient reason to deny certification.

Questions Presented

1. Whether the Superior Court abused its discretion by certifying the Massachusetts class without holding an evidentiary hearing.
2. Whether Kelley satisfied Mass. R. Civ. P. 23(a)'s typicality requirement despite receiving a mailing sponsored by only one defendant and asserting claims against multiple pharmaceutical manufacturers.
3. Whether the defendants' juridical links through CVS and the common patient compliance program were sufficient to permit the class action to proceed against defendants who did not directly contact Kelley.
4. Whether common questions predominated under Mass. R. Civ. P. 23(b) despite potentially individualized questions concerning letter content, medical conditions, emotional reactions, and damages.
5. Whether a class action was superior to other methods of adjudication and whether the possibility that certification would pressure defendants to settle defeated superiority.

Disposition

affirmed